New Delhi, April 4 — Emcure Pharmaceuticals Ltd announced on Friday that its UK-based subsidiary, Tillomed Laboratories Ltd, has signed an agreement to acquire the product portfolio of Manx Healthcare Ltd for approximately £19.7 million (around ₹220 crore).
Strategic Acquisition to Boost Tillomed’s Market Reach
According to the company statement, Tillomed Laboratories has entered into an Asset Purchase Agreement (APA) with Manx Healthcare Ltd and its subsidiaries—Manx Pharma Ltd and Manx Generics Ltd (collectively referred to as Manx). The acquisition includes a comprehensive package comprising product dossiers, marketing authorisations, intellectual property rights, and relevant inventories.Out of the total £19.7 million transaction value, £4.7 million accounts for inventory. An upfront payment of £6.2 million will be made, with the remaining amount structured as milestone payments over the next 18 months.
Strengthening Global Healthcare Access
Ajit Srimal, CEO of Tillomed Laboratories, emphasized the strategic importance of the deal:Milestone in Emcure’s Global Expansion
This acquisition is seen as a pivotal step for Tillomed as it aims to expand its footprint in the UK and European pharmaceutical markets. The company expects the deal to significantly enhance its product offerings and better position it to meet the evolving needs of patients in international markets.With this move, Emcure Pharmaceuticals continues its strategy of strengthening global operations through its subsidiaries and advancing its presence in regulated markets.
Last updated by a enewsx:
